Executives at leading biopharma organizations are revamping the way they develop and market drugs. They are doing this by making market access planning an integral part of their organization and balancing clinical and economic value in product development and commercialization decisions. They have realized that value is not simply a question of determining how much payers will pay for drugs, but the economic value and justification for a given drug in the context of its efficacy, effectiveness and competitive position. One specific approach that is being used is the application of economic and clinical outcomes models earlier in clinical development.
In this short, 30 minute webinar attendees will learn about how the Archimedes Model was applied by Eli Lilly and Company to prioritize early stage compounds for development. The following topics will be covered:
- High level case study
- Brief overview of the Archimedes Model
- Detailed case study
Badri Rengarajan, MD, Medical Director, Archimedes, Inc.
Badri Rengarajan, MD is a senior medical director at Archimedes. His primary responsibilities include leading Archimedes consulting engagements, providing clinical input to the Archimedes Model development efforts, and building relationships with clinical research leaders. He has over ten years of healthcare industry experience, including roles in product development strategy and new product planning, regulatory affairs, market research, and business development. He was previously a director of business development and market research at Nodality (personalized/predictive medicine), regulatory team leader at Genentech, and consultant at McKinsey. Badri earned an AB in biology and public policy from Harvard University and an MD from Yale University.
Who Should Attend?
Pharmaceutical executives and decision makers involved in market access strategy and execution, as well as pipeline portfolio management
Archimedes Inc. is a healthcare modeling and analytics organization. Founded by David Eddy, MD, PhD, a pioneer in evidence based medicine, its core technology – the Archimedes Model – is a clinically realistic, mathematical model of human physiology, diseases, interventions, and healthcare systems. The Model is continually validated by comparing the results of simulated trials to the results of multinational clinical trials and cohort studies, and the results are published.
Through products such as IndiGO and ARCHeS, Archimedes helps people understand the implications of their decisions. For the last 15 years, Archimedes has assisted many organizations in the United States and Europe answer questions related to health and economic outcomes research, policy creation, clinical trial design, and performance improvement. Archimedes, a Kaiser Permanente Innovation, is based in San Francisco, California. For more information about Archimedes and its product offerings, please visit the company’s website at archimedesmodel.com